Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Related to this article
These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Advertisement
Advertisement
Trending on Urology Times
1
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
2
Real-World Outcomes and Learning Curve for Drug-Coated Balloon BPH Therapy
3
Network meta-analysis ranks neoadjuvant options in cisplatin-eligible MIBC
4
The Evolving Landscape of Minimally Invasive BPH Therapy
5